(Q44904373)

English

Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Mathias Zimmermann

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Thomas Unger

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1201-1208

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Beyond blood pressure: new roles for angiotensin II.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Angiotensin AT1/AT2 receptors: regulation, signalling and function

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.5.1201

21 January 2018

Identifiers

10.1517/14656566.5.5.1201

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44904373&oldid=2056284671"